Effects of nitric oxide synthase inhibition and l-arginine on renal haemodynamics in young patients at high cardiovascular risk

Atherosclerosis

Volumn 192, Issue 1, 2007, Pages 155-160

  Schlaich, Markus P ^a   Oehmer, Sebastian ^a   Schneider, Markus P ^a   Delles, Christian ^a   Schmidt, Bernhard M W ^a   Schmieder, Roland E ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Endothelium; Hypercholesterolemia; Nitric oxide; Renal haemodynamics

Indexed keywords

ARGININE; ASCORBIC ACID; N(G) METHYLARGININE; NITRIC OXIDE SYNTHASE INHIBITOR;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; HIGH RISK PATIENT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; KIDNEY BLOOD FLOW; KIDNEY BLOOD VESSEL; KIDNEY PLASMA FLOW; LIPID METABOLISM; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; VASODILATATION;

ADULT; ANTIOXIDANTS; ARGININE; ASCORBIC ACID; HUMANS; HYPERCHOLESTEROLEMIA; MALE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OMEGA-N-METHYLARGININE; OXIDATIVE STRESS; RENAL PLASMA FLOW; SUBSTRATE SPECIFICITY;

EID: 34247163166     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2006.04.025     Document Type: Article

References (23)

1. Vane J.R., Anggard E.E., and Botting R.M. Regulatory functions of the vascular endothelium. N Engl J Med 323 (1990) 27-36
2. Cai H., and Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 87 (2000) 840-844
3. Fleischmann E.H., Schlaich M.P., Schmidt B.M., Oehmer S., and Schmieder R.E. Hypercholesterolaemia and treatment with statins do not alter l-arginine-induced changes of renal haemodynamics. Nephrol Dial Transplant 17 (2002) 1758-1765
4. Delles C., Schneider M.P., Oehmer S., Fleischmann E.H., and Schmieder R.E. l-Arginine-induced vasodilation of the renal vasculature is not altered in hypertensive patients with type 2 diabetes. Diabetes Care 26 (2003) 1836-1840
5. Delles C., Schneider M.P., Oehmer S., Fleischmann I., Fleischmann E.H., and Schmieder R.E. Evidence for increased oxidative stress in the renal vasculature of patients with type 2 diabetes. Nephrol Dial Transplant 19 10 (2004) 2513-2518
6. Schneider M.P., Klingbeil A.U., Delles C., Schmidt B.M., John S., and Schmieder R.E. Vitamin C augments the renal response to l-arginine in smokers. Nephrol Dial Transplant 18 (2003) 1512-1517
7. Panza J.A., Casino P.R., Badar D.M., and Quyyumi A.A. Effect of increased availability of endothelium-derived nitric oxide precursor on endothelium-dependent vascular relaxation in normal subjects and in patients with essential. Circulation 87 (1993) 1475-1481
8. Taddei S., Virdis A., Mattei P., et al. Aging and endothelial function in normotensive subjects and patients with essential hypertension. Circulation 91 (1995) 1981-1987
9. Higashi Y., Oshima T., Ozono R., Matsuura H., and Kajiyama G. Aging and severity of hypertension attenuate endothelium-dependent renal vascular relaxation in humans. Hypertension 30 (1997) 252-258
10. Campo C., Lahera V., Garcia-Robles R., et al. Aging abolishes the renal response to l-arginine infusion in essential hypertension. Kidney Int Suppl 55 (1996) S126-S128
11. Delles C., Jacobi J., Schlaich M.P., John S., and Schmieder R.E. Assessment of endothelial function of the renal vasculature in human subjects. Am J Hypertens 15 (2002) 3-9
12. Smith H.W., Finkelstein N., Aliminosa L., Crawford B., and Garber M. The renal clearance of substituted hippuric acid derivates and other aromatic acids in dogs and man. J Clin Invest 24 (1945) 388-398
13. Ishii M., Ikeda T., Takagi M., et al. Elevated plasma catecholamines in hypertensives with primary glomerular diseases. Hypertension 5 (1983) 545-551
14. Schlaich M.P., Jacobi J., John S., Delles C., Fleischmann I., and Schmieder R.E. Is l-arginine infusion an adequate tool to assess endothelium-dependent vasodilation of the human renal vasculature?. Clin Sci (London) 99 (2000) 293-302
15. Hohenstein B., Hugo C., Hausknecht B., Boehmer K., Riess R., and Schmieder R.E. Increased expression of nitric oxide synthases in human type 2 diabetic nephropathy correlates with clinical risk factors for disease progression. J Hypertens 22 (2004) S364 [abstract]
16. Taddei S., Virdis A., Mattei P., Ghiadoni L., Sudano I., and Salvetti A. Defective l-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation 94 (1996) 1298-1303
17. Clarkson P., Adams M.R., Powe A.J., et al. Oral l-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest 97 (1996) 1989-1994
18. Adams M.R., McCredie R., Jessup W., Robinson J., Sullivan D., and Celermajer D.S. Oral l-arginine improves endothelium-dependent dilatation and reduces monocyte adhesion to endothelial cells in young men with coronary artery disease. Atherosclerosis 129 (1997) 261-269
19. Prior D.L., Jennings G.L.R., and Chin-Dusting J.P. Transient improvement of acetylcholine responses after short-term oral l-arginine in forearms of human heart failure. J Cardiovasc Pharmacol 36 (2000) 31-37
20. McDonald K.K., Zharikov S., Block E.R., and Kilberg M.S. A caveolar complex between the cationic amino acid transporter 1 and endothelial nitric oxide synthase may explain the l-arginine paradox. J Biol Chem 272 (1997) 31213-31216
21. Tsikas D., Boger R.H., Sandmann J., Bode-Boger S.M., and Frolich J.C. Endogenous nitric oxide synthase inhibitors are responsible for the l-arginine paradox. FEBS Lett 478 (2000) 1-3
22. Kaye D.M., Ahlers B.A., Autelitano D.J., and Chin-Dusting J.P. In vivo and in vitro evidence for impaired arginine transport in human heart failure. Circulation 102 (2000) 2707-2712
23. Schlaich M.P., Parnell M.M., Ahlers B.A., Finch S., Zhang W., and Kaye D.M. Impaired l-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects. Circulation 110 (2004) 3680-3686